Background
==========

Breast cancer is the most frequent type of cancer in women both in the developed and the developing world \[[@B1]\]. It is a very heterogeneous disease with regards to its molecular profile \[[@B2]\], and clinical course, which presents great interpatient variability. Although conventional histopathological characteristics remain the most important prognostic determinants of survival \[[@B3]\], there is a continuous search for new biomarkers or stage models that could help predicting clinical evolution \[[@B4]\], or improving therapy selection. In this regard, genetic variations in carcinogenesis-related processes are natural candidates for exploring new prognostic factors or potential targets for specific therapies \[[@B5],[@B6]\].

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK) receptor of the ErbB family, whose activation leads to mitogenic signaling \[[@B7]\]. EGFR is frequently overexpressed in many tumors, including breast cancer, and its activation contributes to unrestricted proliferation, advanced stages of disease, resistance to conventional treatments, and poor prognosis \[[@B8]\]. Despite the recognition that EGFR overexpression in breast tumors may affect disease progression \[[@B8]\], the responses of anti-EGFR therapies in breast cancer are not fully satisfactory \[[@B9]\], and the reasons for this clinical variability are not fully understood.

The *EGFR* gene, located at 7p12.3-p.1, contains multiple polymorphisms \[[@B10]\], two of which are recognized for their functional effects: a dinucleotide (CA)n repeat sequence polymorphism in intron 1 (rs72554020) affects gene transcription \[[@B11]\], and appears to modulate EGFR expression in breast tumors \[[@B12]\], and a single nucleotide change (G → A) in exon 13 leads to an Arginine (Arg) → Lysine (Lys) substitution in codon 497 (rs11543848), resulting in attenuated TK activity, with consequent reductions in ligand binding, growth stimulation, and induction of proto-oncogenes *myc*, *fos*, and *jun*\[[@B13]\].

In the present work, we aimed to describe the frequency of these two *EGFR* polymorphisms among Brazilian breast cancer patients, and to evaluate their impact on breast cancer prognosis, exploring the effects of *(CA)n* polymorphism on EGFR transcript levels, and the associations of both polymorphisms with histopathological features and prognostic estimates.

Materials and methods
=====================

Subjects and study design
-------------------------

The study population consisted of a prospective cohort of Brazilian women with first diagnosis of unilateral breast cancer and no distant metastases, admitted at the Brazilian National Cancer Institute (INCA) during the period from February 2009 to April 2011, and who were assigned for tumor resection as their first therapeutic approach. The recruitment occurred before surgery, but the inclusion was only completed after diagnosis confirmation by histopathological evaluation of the resected tumor. The study protocol was approved by the Ethics Committee of the Brazilian National Cancer Institute (INCA \#129/08), and all patients gave written consent to participate. The REMARK guidelines (REporting recommendations for tumor MARKer prognostic studies) were followed \[[@B14]\].

Histopathological characterization
----------------------------------

The histopathological evaluation of resected tumors was performed following institutional routine procedures, and all individual data were obtained from electronic medical records. The histopathological characterization was based on the TNM classification by the American Joint Committee on Cancer \[[@B15]\] and on the Elston Ellis histological grading system \[[@B16]\].

The data on hormone receptors, i.e. Estrogen Receptor (ER), and Progesterone Receptor (PR), and on the Human Epidermal growth factor Receptor 2 (HER2) status were used for biological classification of the tumors, as proposed by Huober *et al*. \[[@B17]\]. The Estimated Recurrence Risk (ERR) was inferred by a combination of all histopathological features, as proposed by the Early Breast Cancer Trialists' Collaborative Group \[[@B18]\], with the following categories: "Low Risk", characterized by the presence of \[age ≥ 35 years, N0 (absence of tumor cells in lymph nodes), G1 (histological grade 1), T1 (tumor size lower than 2 cm), (ER+ or PR+), HER2-\], and absence of peritumoral vascular invasion; "Intermediate Risk", characterized by N0 in the presence of \[age \< 35 years, or T ≥ 2, or G ≥ 2, or (ER- and PR-), or HER2+\], or by N1 (presence of tumor cells in 1 to 3 lymph nodes) in the presence of \[HER2-, and (ER + or PR+)\]; and "High Risk", characterized by N1 in the presence of \[HER2+, or (ER- and PR-)\], or by N ≥ 2 (presence of tumor cells in more than 3 lymph nodes).

Genotyping analyses
-------------------

Peripheral blood samples (3 mL) were collected from the subjects, and DNA was extracted using the Blood Genomic Prep Mini Spin Kit (GE Heathcare, Buckinghamshire, UK), following the procedures recommended by the manufacturer. The genotyping analyses were performed using PCR-RFLP for the SNP *R497K* (rs11543848) or by capillary electrophoresis for the (CA)n repeat polymorphism in intron 1 (rs72554020). The PCR amplifications were performed with the following primers (Life Thechnology, Carlsbad, CA, USA): 5′-AGGTCTGCCATGCCTTGT-3′ (sense) and 5′-CAACGCAAGGGGATTAAAGA-3′ (antisense) for *R497K*; or 5′-TTCTCCTCAAAACCCGGAGAC-3′ labeled with 6-FAM™ (sense) and 5′-GTCACGAAGCCAGACTCGCT-3′ for (CA)n repeat (antisense). The *R497K* PCR products (5 μL) were digested with 5U of *Bst*N1 restriction enzyme (New England BioLabs, Northbrook, IL, USA) at 60°C for 3 hours, and the digestion products were resolved on 2% agarose gel and stained with ethidium bromide for visualization under UV light. The digestion of the homozygous G alleles (Arginine) produced two fragments (100 bp and 56 bp), whereas the homozygous A alleles (Lysine) remained intact (156 bp). The method was validated by direct sequencing of four samples of each genotype.

The (CA)n repeat PCR products (0.5 μl) were denatured at 95°C for 3 min in the presence of 0.5 μl of the GeneScan™ 400HD ROX molecular weight standard (Applied Biosystems, Foster City, CA, USA) and 9.0 μl of Hi-Di™ Formamide (Life Thechnology, Carlsbad, CA, USA), refrigerated to 4°C for 2 min, and then submitted to separation by capillary electrophoresis in ABI Prism® 3130 Genetic Analyzer, using POP7™ polymer (Applied Biosystems, Foster City, CA, USA). The analyses were performed using the GeneMapper® Software v.3.7 (Applied Biosystems, Foster City, CA, USA). The PCR products identified as homozygous, i.e. those presenting a single retention time at the capillary electrophoresis, were submitted to direct sequencing, using the BigDye® Terminator Kit (Applied Biosystems, Foster City, CA, USA), in order to establish a correspondence between each retention time and the respective number of CA repeats (or allele length).

Quantification of EGFR mRNA
---------------------------

Fresh specimens of breast tumors were dissected by clinical pathologists after tumor resection, frozen in liquid N~2~, and stored at the Brazilian National Bank of Tumors (BNT-INCA). Frozen sections of breast specimens (with approximately 2 mm) were used for RNA isolation, which was performed using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), following the manufacturer's instructions. The RNA samples were stored in RNAse-free distilled water at -80°C, and the corresponding cDNA was synthesized using 2 μg of RNA, with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions.

The relative quantification of *EGFR* transcripts was performed using quantitative real-time RT-PCR (TaqMan) assays, in an ABI PRISM 7500 Sequence Detector System (Applied Biosystems, Foster City, CA, USA). Each reaction contained: cDNA templates (approximately 40 ng), 10 μl of reaction mix containing 5 μl Taqman® Gene Expression Master Mix, and Taqman® probes, which were as follows: *EGFR* Hs01076078_m1 (with FAM), *PPIA* 4326316E (with VIC) (Applied Biosystems, Foster City, CA, USA). The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 min, followed by 40 cycles of 95°C denaturation for 15 sec, and annealing at 60°C for 1 min. The experiments were carried out in 96-well plates, including a nontemplate control, and a reference control, consisting of cDNA obtained from a commercial Human Mammary Gland (HMG) total RNA (Clontech Laboratories, Mountain View, CA, USA). The relative quantification of *EGFR* mRNA was calculated as the average 2^-ΔΔCt^, where ΔΔCT = ΔCT~*EGFR*~ - ΔCT~HMG,~ and ΔCT~*EGFR*~ = Ct~*EGFR*~ - Ct~*PPIA*~*,* and ΔCT~*HMG*~ = Ct~*HMG*~ - Ct~*PPIA*~. All data were generated in triplicates and expressed as median +/- SD with the 25--75 percentiles.

Statistical analyses
--------------------

A descriptive study of the cohort was conducted, presenting measures of central tendency and dispersion for continuous variables, or relative frequencies for each categorical variable. Allelic and genotypic frequencies were derived by gene counting. The histopathological features were dichotomized for better and worse prognostic values, and their associations with *EGFR* genotypes were evaluated by the *Chi*-square or Fisher's exact tests. In the cases of significant associations between *EGFR* genotypes and independent histopathological variables, the odds ratios (OR) and their respective 95% confidence intervals (95% CI) were tested for linear-by-linear associations, with calculation of trend significances (P~trend~), and definition of phenotypic inheritance models. The odds ratios between *EGFR* phenotypic groups and histopathological categorical features were adjusted for all other independent clinical variables (OR~adjusted~) using multiple regression analyses. The comparison of the relative quantities of *EGFR* mRNA as a function of histopathological features or *EGFR* genotypes was performed with the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA), using the non-parametric Mann--Whitney *U*-test for comparison of two groups, or the Kruskal-Wallis test for comparison of multiple groups. All other statistical analyses were conducted using SPSS 13.0 for Windows (SPSS Inc., Chicago, Illinois). The threshold for significance was set at P \< 0.05.

Results
=======

Characterization of the cohort
------------------------------

A total of 576 patients were recruited when admitted for surgery, and 528 had the diagnosis and inclusion criteria confirmed after pathological evaluation of their resected tumor. Blood samples were available for 511 cases, and 508 of them had good DNA quality for genotyping assays. Table [1](#T1){ref-type="table"} presents the main clinical and histopathological characteristics, as well as the genotypic distribution of *EGFR* polymorphisms for the 508 patients evaluated. The median age was 59 years old, ranging from 27 to 92.

###### 

**Histopathological characteristics, tumor classification and*EGFR*genotypes in Brazilian breast cancer patients**

  **Independent variables**    **n**   **%**   **Tumor classifications**    **n**    **%**
  --------------------------- ------- ------- --------------------------- --------- -------
  Histological type                                                                     
   Ductal invasive              440    8606                0                 35       7.1
   Ductal *in situ*             34      6.7               IA                 157     31.7
   Lobular *in situ*             1      0.2               IB                  7       1.4
   Lobular invasive             29      5.7              II A                148     29.9
   Mixed                         4      0.8              II B                70      14.1
                                                         III A               52      10.5
  Tumor grade                                            III B                1       0.2
   Grade 1                      60     12.6              III C               25       5.1
   Grade 2                      193    40.5             missing              13         
   Grade 3                      223    46.8                                             
   Missing                      32             Biological classifiation                 
                                                       luminal A             293     64.8
  Tumor size                                           luminal B             89       5.8
   pTis                         35      7.1            HER2 like             26       5.8
   pT1                          226    45.7         triple negative          44       9.7
   pT2                          220    44.4             missing              56         
   pT3                          13      2.6                                             
   pT4                           1      0.2         ERR categories                      
  Missing                       13                        low                20       4.2
                                                     intermediate            357     75.5
  Lymph node status                                      high                96      20.3
   pN0                          312    61.4             missing              35         
   pN1                          120    23.6                                             
   pN2                          50      9.8                                             
   pN3                          26      5.1                                             
  Estrogen receptor                               **EGFR Genotypes**       ***n***   **%**
   Negative                     76     15.0             *R497K*                         
   Positive                     414    84.5            *Arg/arg*             308     61.0
   Missing                      18                     *Arg/Lys*             176     34.9
                                                       *Lys/Lys*             21       4.2
  Progesterone receptor                                 missing               3         
   Negative                     134    26.4                                             
   Positive                     355    72.6                                             
   Missing                      19                                                      
                                                        *(CA)n*                         
  HER2                                               *Short/Short*           108     22.6
   Negative                     378    74.4          *Short/Long*            230     48.2
   Indeterminate                15      3.2           *Long/Long*            139     29.1
   Positive                     73     15.7             missing              31         
   Missing                      42                                                      

Data are expressed as the number of patients and their respective percentage in each category. *(CA)n Short*: n≤ 16; *(CA)n Long*: n \> 16. *Abbreviations*: *ERR* Estimated Recurrence Risk, *HER2* Human Epidermal growth factor Receptor 2.

Characterization of *EGFR* polymorphisms
----------------------------------------

The genotyping of the *R497K* polymorphism was obtained for 505 patients, whereas the characterization of the number of (CA)n repeats by electrophoresis was conclusive in 477 cases (Table [1](#T1){ref-type="table"}). The frequency of the variant *R497K* allele (*Lys*) was 0.21 (95% CI = 0.19-0.24).

The evaluation of the (CA)n lengths indicated a range of 14 to 24 repeats (Figure [1](#F1){ref-type="fig"}), comprehending 11 alleles and 37 genotypes. The most frequent allele was *(CA)*~*16*~ (0.43; 95% CI = 0.40--0.46), which was taken as the cut-off length to group *Short* alleles. All the other variant alleles, with more than 16 (CA) repeats were considered as *Long* alleles. Thus, the genotypic distribution used for further analyses was: *Short/Short* (reference homozygous genotype), S*hort/Long* (heterozygous) and *Long/Long* (variant homozygous genotype).

![**Evaluation of the (CA)n lengths in the Brazilian cohort of breast cancer patients: (CA)n ≤ 16 were grouped as*Short*alleles, whereas (CA)n \> 16 were grouped as*Long*alleles.**](1471-2407-14-190-1){#F1}

Characterization of EGFR mRNA expression in breast tumors, and evaluation of the influence of *(CA)n* genotypes and of histopathological characteristics
--------------------------------------------------------------------------------------------------------------------------------------------------------

The *EGFR* mRNA expression levels were evaluated in fresh-frozen tumor samples from 129 patients. Table [2](#T2){ref-type="table"} shows the main clinical and histopathological characteristics, as well as the genotypic distribution of *EGFR* polymorphisms in this subcohort. The data are presented in comparison with those described for the general population (Table [1](#T1){ref-type="table"}). The results indicate that the subcohort whose tumors were used for expression analyses is similar to the general population, except for tumor size, and nodal status, which tend to be higher in the former. This difference is caused by the institutional biobank policy, which restricts collection of tumors with less than 1 cm for non-diagnostic purposes.

###### 

Characterization of a subcohort used for tumoral RNA analyses, and comparison with the complete cohort

                               **Complete cohort**   **Tumor subcohort**               
  --------------------------- --------------------- --------------------- ----- ------ -----------
              Age                                                                            
         \> 35 years-old               496                  97.6           125   96.9     0.63
         ≤ 35 years-old                12                    2.4            4    3.1         
        Family history                                                                       
               No                      400                  87.7           85    85.9     0.61
              Yes                      56                   12.3           14    14.1        
       Histological type                                                                     
           *in situ*                   35                    7.0            2    1.6    **0.018**
            Invasive                   462                  93.0           127   98.4        
          Tumor grade                                                                        
            Grade 1                    60                   12.6           10    7.8      0.14
          Grade 2 or 3                 416                  87.4           117   90.7        
          Tumor size                                                                         
           pT ≤ 2 cm                   226                  49.1           42    33.1   **0.001**
           pT \> 2 cm                  234                  50.9           85    66.9        
       Lymph node status                                                                     
           pN0 or pN1                  432                  85.0           99    76.7   **0.024**
           pN2 or pN3                  76                   15.0           30    23.3        
         ER/PR status                                                                        
        Negative (both)                76                   15.5           27    20.9     0.14
       Positive (either)               414                  84.5           102   79.1        
          HER2 status                                                                        
            Negative                   378                  83.8           102   81.0     0.45
            Positive                   73                   16.2           24    19.0        
   Biological classification                                                                 
      Non triple negative              440                  90.9           112   86.8     0.17
        Triple negative                44                    9.1           17    13.2        
       *EGFR* genotypes                                                                      
            *R497K*                                                                          
           *Arg/Arg*                   308                  61.0           82    64.1     0.380
           *Arg/Lys*                   176                  34.9           38    29.7  
           *Lys/Lys*                   21                    4.2            8    6.3         
            *(CA)n*                                                                          
         *Short/Short*                 108                  22.6           30    23.6     0.358
          *Short/Long*                 230                  48.2           68    53.5        
          *Long/Long*                  139                  29.1           29    22.8        

*Abbreviations*: *ER* Estrogen receptor, *PR* Progesterone receptor, *HER2* Human Epidermal groth factor Receptor 2. Statistically significant differences are presented in bold characters.

The relationship between *EGFR* mRNA expression levels and *(CA)n* genotypes or prognostic categories of breast tumors were explored (Figure [2](#F2){ref-type="fig"}). The results indicate no differences related to *(CA)n* genotypes (Figure [2](#F2){ref-type="fig"}A), whereas the lymph node status (Figure [2](#F2){ref-type="fig"}B) and the biological subclassification (Figure [2](#F2){ref-type="fig"}C) showed significant influences. The *EGFR* mRNA expression levels were significantly higher for patients with worse lymph node status, as well as for triple-negative tumors when compared to all other subgroup classifications (p = 0.003). As a consequence of these two associations, patients with higher ERR presented higher *EGFR* mRNA expression levels (Figure [2](#F2){ref-type="fig"}D).

![**Expression levels of*EGFR*mRNA in breast tumors according to*EGFR*genotypes and histopathological prognostic estimates: (A)***(CA)n* genotypes, presented as *Short/Short*, (n = 30) *Short/Long* (n = 68) or *Long/Long* (n = 29); **(B)** Lymph node status, presented as pN0 or pN1 (n = 99) or pN2 or pN3 (n = 30); **(C)** Biological classification of tumors, presented as Luminal A (n = 69), Luminal B (n = 30), HER2 like (n = 10) or triple negative (n = 17); **(D)** Estimated Recurrence Risk (ERR), divided in "Low or intermediate" (n = 50) and "High" (n = 50).](1471-2407-14-190-2){#F2}

Association between *EGFR* genotypes and prognostic variables
-------------------------------------------------------------

Table [3](#T3){ref-type="table"} presents the distribution of *R497K* and *(CA)n* genotypes according to prognostic categories. The distribution of *R497K* genotypes was statistically different as a function of the lymph node status, whereas the distribution of *(CA)n* genotypes was statistically different as a function of the PR status.

###### 

**Distribution of the*R497K*and*(CA)n*genotypes according to prognostic variables**

   **Prognostic variables**          ***R497K***          ***(CA)n***                                          
  --------------------------- ----- ------------- ------ ------------- ----------- ------ ------ ------ ------ -----------
              Age                                                                                                    
         \> 35 years-old       493      61.7       34.1       4.3         0.06      466    22.7   48.5   28.8     0.48
         ≤ 35 years-old        112      33.3       66.7       0.0                    11    18.2   36.4   45.5        
       Familial history                                                                                              
               No              400      60.0       36.0       4.0         0.99      376    21,5   49,7   28,7     0.38
              Yes              56       60.7       35.7       3.6                    53    26,4   39,6   34.0        
       Histological type                                                                                             
           *in situ*           35       62.9       34.3       2.9         0.91       33    15.2   48.5   36.4     0.44
            Invasive           459      61.0       34.6       4.4                   434    23.3   48.6   28.1        
          Tumor grade                                                                                                
            Grade 1            60       56.7       40.0       3.3         0.64       58    25.9   46.6   27.6     0.74
          Grade 2 or 3         413      61.3       34.1       4.6                   389    21.3   48.8   29.8        
          Tumor size                                                                                                 
           pT ≤ 2 cm           224      59.4       36.6       4.0         0.65      214    22.9   45.3   31.8     0.24
           pT \> 2 cm          233      62.7       32.6       4.7                   218    23.4   51.8   29.8        
       Lymph node status                                                                                             
           pN0 or pN1          429      58.0       37.3       4.7       **0.005**   405    22.7   47.2   30.1     0.47
           pN2 or pN3          76       77.6       21.1       1.3                    72    22.2   54.2   23.6        
           ER status                                                                                                 
            Negative           76       68.4       27.6       3.9         0.38       72    26.4   51.4   22.2     0.29
            Positive           411      60.1       35.5       4.4                   387    21.2   47.8   31.0        
           PR status                                                                                                 
            Negative           133      63.2       32.3       4.5         0.87      128    28.1   50.0   21.9   **0.031**
            Positive           353      60.9       34.8       4.2                   330    19.4   47.9   32.7        
          HER2 status                                                                                                
            Negative           376      59.3       35.6       5.1         0.13      356    21.9   50.0   28.1     0.30
            Positive           72       65.3       34.7       0.0                    67    20.9   41.8   37.3        
   Biological classification                                                                                         
           Luminal A           291      58.8       36.4       4.8         0.68      275    20.0   49.8   30.2     0.35
           Luminal B           88       60.2       36.4       3.4          83       21.7   43.4   34.9         
           HER2 like           26       73.1       26.9       0.0          24       37.5   41.7   20.8         
        Triple negative        44       63.6       29.5       6.8                    42    23.8   54.8   21.4        

Data are expressed as the number of patients and respective percentages in each category. *(CA)n Short*: n ≤ 16; *(CA)n Long*: n \> 16. *Abbreviations*: *ER* Estrogen Receptor, *PR* Progesterone Receptor, *HEr2* Human Epidermal groth factor Receptor 2. Statistically significant differences are presented in bold characters.

The association between *R497K* genotypes and lymph node status, or between *(CA)n* genotypes and the PR status is further explored in Figure [3](#F3){ref-type="fig"}. Figure [3](#F3){ref-type="fig"}A shows that patients with the heterozygous genotype *Arg/Lys* presented lower proportion of the worse lymph node status (pN2 or pN3), when compared to the reference homozygous genotype *Arg/Arg* (OR = 0.42; 95% CI = 0.23--0.76), whereas among patients with the homozygous variant genotype *Lys/Lys* (n = 21), there was only 1 case of pN2 or pN3 (OR = 0.21; 95% CI = 0.028--1.60). These results indicate that the magnitude of the association between *R497K* polymorphism and lymph node status depends on the number of variant *Lys* alleles (P~trend~ = 0.001). Similarly, Figure [3](#F3){ref-type="fig"}B shows the impact of the number of variant *(CA)n* alleles on the proportion of negative PR status. The results indicate an apparently progressive effect of the number of long *(CA)n* alleles (P~trend~ = 0.008). Thus, patients with the *Short/Long* genotype showed a slightly lower proportion of negative PR status when compared to the reference *Short/Short* genotype (OR = 0.72; 95% CI = 0.44--1.19), and a significant protective effect was observed for the variant *Long/Long* genotype (OR = 0.46; 95% CI = 0.26--0.83).

![**Significant influences of*EGFR*polymorphisms on histopathological features of brast cancer: (A)** Proportion of lymph node status (pN2 or pN3/pN0 or pN1) according to *R497K* genotypic groups; **(B)** proportion of progesterone receptor status (PR negative/PR positive) according to *(CA)n* genotypic groups.](1471-2407-14-190-3){#F3}

Interaction between *EGFR* polymorphisms
----------------------------------------

The above trend analyses suggested an inheritance model of codominance for the association between *R497K* polymorphism and lymph node status and of recessiveness for *(CA)n Long* allele and PR status. Thus, the genotypes *Arg/Lys* and *Lys/Lys* were grouped for evaluation of their impact on lymph node status, whereas the *(CA)n Long/Long* genotype was evaluated in comparison with the combined *Short/Short* and *Short/Long* genotypes for its effect on the PR status. The two *EGFR* polymorphisms were also evaluated in a combined analysis in order to investigate a possible interaction between them on the distribution of breast cancer prognostic features (Table [4](#T4){ref-type="table"}).

###### 

Impact of EGFR polymorphisms on histopathological features and prognostic estimates of breast cancer

                     ***R497K*variant genotypes**   ***(CA)n*variant genotypes**   ***EGFR*combined variant genotypes**                                                             
  ----------------- ------------------------------ ------------------------------ -------------------------------------- -------------- ------------- -------------- -------------- -------------
   Complete cohort               0.32                           0.34                               0.50                       0.42          0.74           0.74           0.22          0.25
                             (0.17-0.59)                    (0.19-0.63)                        (0.30-0.81)                (0.19-0.91)    (0.40-1.32)   (0.43-1.25)    (0.07-0.75)    (0.09-0.71)
    **\< 0.001**              **0.001**                      **0.005**                          **0.030**                     0.53          0.26        **0.018**      **0.005**    
      Luminal A                  0.34                           0.38                               0.35                        NA           0.62           0.60           0.32          0.24
                             (0.15-0.75)                    (0.18-0.80)                        (0.17-0.75)                               (0.29-1.36)   (0.27-1.32)    (0.092-1.12)   (0.06-1.03)
      **0.007**               **0.011**                      **0.005**                                                        0.22          0.20          0.075        **0.038**    
      Luminal B                 0.057                          0.060                               0.58                      0.080          1.29           1.29            NC           0.61
                             (0.006-0.53)                   (0.007-0.53)                       (0.21-1.60)                (0.012-0.54)   (0.35-4.72)   (0.48-3.48)                   (0.12-3.10)
      **0.012**               **0.012**                         0.29                           **\< 0.001**                   0.26          0.62                          0.54      
      HER2-like                  0.18                           0.22                               0.27                        NA           1.14           2.91            NC            NC
                             (0.02-2.02)                    (0.02-2.28)                        (0.05-1.64)                               (0.15-8.59)   (0.27-31.21)                        
        0.18                     0.22                           0.14                                                          0.90          0.36                                    
   Triple negative               5.2                            5.1                                2.0                         NA            NC             NC             NC            NC
                             (0.48-55.27)                   (0.48-54.03)                       (0.48-8.40)                                                                                 
                                 0.17                           0.18                              0.349                                                                                    

*R497K* variant genotypes include *Arg/Lys* and *Lys/Lys.* The genotype *Arg*/*Arg* was taken as reference for OR calculation*; (CA)n* variant genotypes include two *Long* alleles in combination (*Long/Long)*, where the *Long* allele corresponds to (CA)n lengths with more than 16 repeats. The genotypes *Short/Short* and *Short/Long* were considered together as reference for OR calculation. *EGFR* combined variants include patients with genotypes *Arg/Lys* or *Lys/Lys* for *R497K* and *Long/Long* for *(CA)n.* The reference genotypes were *R497K Arg/Arg* and *(CA)n Short/Shor*t or *Short/Long.* The OR calculation for lymph node status was adjusted for age, hystological type, tumor grade, tumor size, and for ER, PR and HER2 status. The OR calculation for PR status was adjusted for age, hystological type, tumor grade, tumor size, lymph node status and for ER and HER2 status. The OR calculation for TNM status was adjusted for age, hystological type, tumor grade and for ER, PR and HER2 status. Statistically significant differences are presented in bold characters. *Abbreviations*: *TNM* Tumor staging according to tumor size, lymph node status and distant metastases, *ERR* Estimated Recurrence Risk, *PR* Progesterone Receptor, *HER2* Human Epidermal growth factor Recetor 2, *NA* not applicable, *NC* not calculated (the number of samples was not sufficient for OR calculation).

The results indicate a significantly protective effect of the *Lys* allele on the proportion of the worse lymph node status after adjustment for other independent individual prognostic variables. As a consequence, patients carrying the *Lys* allele showed lower TNM status and lower ERR. With regards to the *(CA)n* polymorphism, the association between *(CA)n Long/Long* genotype and PR negative status also remained significant after adjustment for other independent individual prognostic variables (OR~adjusted~ = 0.42; 95% CI = 0.19-0.91), but did not affect TNM status or the ERR. When the two *EGFR* polymorphisms are present, there is lower TNM status (OR~adjusted~ = 0.22; 95% CI = 0.07-0.75) and lower ERR (OR = 0.25; 95% CI = 0.09-0.71).

The stratification of breast tumors according to their biological classification indicates that the association between combined variant *EGFR* polymorphisms and better lymph node status occurs for tumors classified as luminal A, but not for the other biological subtypes.

Discussion
==========

The distribution of the two *EGFR* functional polymorphisms in the Brazilian population was not known before the current study. Our data indicate a frequency of 0.21 (95% CI = 0.19 -- 0.24) for the *497 K* (*Lys* allele), and of 0.43 (95% CI = 0.40 -- 0.46) for the *(CA)*~*16*~. These results are similar to the frequencies reported for Europeans and North-Americans (including African-Americans), either for *R497K* polymorphisms \[[@B19],[@B20]\] or *(CA)n*\[[@B12],[@B21]\]. Asian populations, however, appear to have higher frequencies of the *Lys* allele \[[@B22],[@B23]\], and different patterns of *(CA)n* alleles \[[@B12],[@B21],[@B24],[@B25]\].

One difficulty of evaluating the effects of *(CA)n* polymorphism in gene transcriptional activity *in vivo* is the vast distribution of the number of (CA) repeats, with various possible heterozygous genotypes, and no clear model on how the two alleles interact for the final cell phenotype. Amador *et al*. \[[@B26]\] considered the sum of CA repeats of both alleles and showed an inverse correlation between this combined length and the levels of *EGFR* mRNA in head and neck cancer cell lines. Buerger *et al*. \[[@B12]\], studying breast tumors, considered the length of the smaller allele, and showed a non-significant tendency for lower EGFR protein expression with increasing allele length. Accordingly, Buerger *et al*. \[[@B27]\] showed that breast tumors from Japanese patients, who present high frequencies of *(CA)*~*20*~ and other long alleles, had lower amounts of EGFR protein than tumors from German patients, who have a predominance of *(CA)*~*16*~ and other short alleles. Other authors, however, found no correlation between the length of the (CA)n region and the relative quantification of *EGFR* mRNA \[[@B28]\] or EGFR protein expression \[[@B29]\].

Our data confirm the great dispersion of (CA) lengths and indicate great variability on the expression of *EGFR* mRNA, with no apparent inverse correlation between the number of (CA) repeats, considering either the smaller allele or the combined length within each genotype (data not shown). In order to investigate a possible effect of somatic mutations on the tumoral *(CA)n* genotype, we evaluated a set of 40 tumor samples. The number of CA repeats was preserved in relation to genomic DNA in all cases (data not shown). Although we did not extend such analyses to all patients, it appears that mutational events, such as loss of heterozigosity, are not affecting the *EGFR* locus of breast tumors. Nevertheless, an accurate characterization of the impact of *EGFR* polymorphisms on the gene transcriptional activity *in vivo* would ideally include quantification of gene amplification in the tumors \[[@B27]\]. In addition, there are two other *EGFR* polymorphisms (-*216G/T* or rs712829 and *-191C/A* or rs712830), located in the promoter region, which might have functional impact on *EGFR* transcriptional activity \[[@B30]\]. Finally, epigenetic variations may also interfere with *EGFR* expression \[[@B31]\].

The evaluation of the impact of *EGFR* polymorphisms on histopathological and molecular characteristics of breast cancer indicated significant association between *R497K* variant genotypes and better lymph node status, corroborating the findings of Kallel *et al*. \[[@B32]\], and between *Long*/*Long (CA)n* genotypes and positive PR status. These two associations seem protective in relation to breast cancer evolution, since a greater number of affected lymph nodes increases the risk of systemic metastasis \[[@B33]\], and the lack of PR expression increases the risk of disease progression, especially in post-menopausal women \[[@B34]\].

With regards to the molecular mechanisms underlying lymph node metastases, EGFR appears to activate integrins \[[@B35]\] and metaloproteinases \[[@B36]\], favoring cell differentiation towards an invasive phenotype. The association between the variant allele (*Lys*) and better lymph node status appear to corroborate the notion of reduced signaling with the variant EGFR isoform \[[@B13]\], leading to lower invasiveness, which reinforce the role of EGFR in breast cancer pathogenesis.

The interaction between the EGFR activity and the PR status might occur via a cross-talk mechanism between steroid and growth factor receptors \[[@B37]\], resulting in activation of the PIK3-Akt-mTOR pathway, which appears to negatively modulate the transcriptional activity of the PR \[[@B38]\]. This negative modulation of ER-mediated functions in breast cancer via EGFR signaling may underlie the mechanism of resistance to hormone therapy observed in tumors with high EGFR expression \[[@B39]\]. Taken together, the association between *EGFR* polymorphisms and lymph node metastases and negative PR status appear to corroborate the role of EGFR in breast cancer pathogenesis.

The combined presence of *Long/Long (CA)n* genotypes and *Lys R497K* alleles appears to favor better prognostic estimates in breast cancer. Other studies involving different types of cancer also point to an interaction between the two *EGFR* polymorphisms, with a combined protective effect in relation to disease progression. Zhang *et al*. \[[@B40]\], evaluating pelvic recurrence in patients with rectal cancer treated with chemoradiation, showed that the highest risk for local recurrence was seen in patients with the reference genotypes, i.e., both 497 *Arg* alleles and \<20 CA repeats. Bandrés *et al*. \[[@B41]\], studying head and neck cancer, showed that patients with at least one 497 *Arg* allele and both (CA)n repeats ≤ 16 presented higher risk of death. Press *et al*. \[[@B42]\], studying metastatic colon cancer, found that men with the *Arg/Arg* genotype and two short alleles (\< 20 CA repeats) had shorter overall survival than men with the *Lys/Lys* or *Arg/Lys* variant genotypes and any long allele (≥ 20 CA repeats).

The stratification of breast tumors according to their biological subtypes suggests that the apparently protective effects of *EGFR* polymorphisms are characteristic of luminal A tumors. This apparently selective effect of *EGFR* polymorphisms might be due to the lower genomic instability of luminal A tumors in relation to other subtypes, which present more aggressive phenotypes due to superposed molecular alterations \[[@B43]\]. Nevertheless, the small number of non-luminal A tumors limits the statistical power of the analyses, and the confidence of this assumption. In addition, the apparently favorable associations of *EGFR* polymorphisms with prognostic features at diagnosis cannot be considered as actually predictive of disease progression or therapy response,

Conclusions
===========

In conclusion, the current results indicate a potential benefit of *EGFR* polymorphisms as independent prognostic factors, especially in early-stage luminal A tumors, as they might contribute to identify patients at higher risk of progression. We propose that *EGFR* genotyping should be further evaluated for their prognostic value in prospective studies of breast cancer survival.
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